KAY MILK FROTHER STEAM WAND CLEANER България - български - Ecolab

kay milk frother steam wand cleaner

ecolab deutschland gmbh -

KAY MILK LINE CLEANER България - български - Ecolab

kay milk line cleaner

ecolab deutschland gmbh -

TUDOMAX 10 mg/g, powder for use in drinking water/milk 10.00 mg/g България - български - БАБХ (Българска агенция по безопасност на храните)

tudomax 10 mg/g, powder for use in drinking water/milk 10.00 mg/g

sp veterinaria s.a. - Бромгексин - прах за прилагане във вода за пиене/мляко - 10.00 mg/g - говеда, патици, пилета, прасета, пуйки, телета

Advantan Milk  0,1 % cutaneous emulsion България - български - Изпълнителна агенция по лекарствата

advantan milk  0,1 % cutaneous emulsion

bayer pharma ag, - Метилпреднизолона ацепонат - 0,1 % cutaneous emulsion

Opdivo Европейски съюз - български - EMA (European Medicines Agency)

opdivo

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - Антинеопластични средства - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

DOXX-SOL 500 mg/g powder for use in drinking water/milk replacer for pre-ruminant calves, pigs and chickens 500 mg/g България - български - БАБХ (Българска агенция по безопасност на храните)

doxx-sol 500 mg/g powder for use in drinking water/milk replacer for pre-ruminant calves, pigs and chickens 500 mg/g

huvepharma nv - Доксициклин гиклат - прах за прилагане във вода за пиене - 500 mg/g - говеда, пилета, свине, телета

HIDROCOL, 4000000 IU/ml solution for use in drinking water/milk 4 000 000 IU/ml България - български - БАБХ (Българска агенция по безопасност на храните)

hidrocol, 4000000 iu/ml solution for use in drinking water/milk 4 000 000 iu/ml

s.p. veterinaria s.a. - Колистин - разтвор за прилагане във вода за пиене/мляко - 4 000 000 iu/ml - агнета, пилета, прасета, пуйки, телета

PAROFOR 140 mg/ml solution for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs 200 mg/ml България - български - БАБХ (Българска агенция по безопасност на храните)

parofor 140 mg/ml solution for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs 200 mg/ml

huvepharma nv - Сулфат паромомицин - разтвор за прилагане във водата за пиене/млако или млекозаместител - 200 mg/ml - говеда, прасета

PAROFOR 70 000 IU/g powder for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs 100 mg/g България - български - БАБХ (Българска агенция по безопасност на храните)

parofor 70 000 iu/g powder for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs 100 mg/g

huvepharma nv - Сулфат паромомицин - прах за прилагане във вода за пиене - 100 mg/g - прасета, телета

APRAVET 552 IU/mg powder for use in drinking water/milk for pigs, calves, chickens and rabbits 552 IU/mg България - български - БАБХ (Българска агенция по безопасност на храните)

apravet 552 iu/mg powder for use in drinking water/milk for pigs, calves, chickens and rabbits 552 iu/mg

huvepharma nv - Апрамицину - Прах за прилагане във водата за пиене - 552 iu/mg - зайци, пилета, прасета, телета